Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BM-219 by Suzhou Biomissile Biopharmaceutical for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
BM-219 is under clinical development by Suzhou Biomissile Biopharmaceutical and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According...